Among them, the second generation of peripheral CB1R-targeted neutral antagonist or inverse agonist with limited access to the central nervous system is holding great promise to be the next blockbuster for obesity therapy. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.